A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: Sintilimab Combined With Apatinib and Capecitabine
Objective Response Rate (ORR), Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., 1 year after the last patient's enrollment
Disease Control Rate (DCR), Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., 1 year after the last patient's enrollment|Duration of Response (DoR), Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., 1 year after the last patient's enrollment|Overall survival(OS), the date of Death of any causes since the date of enrollment, 1 year after the last patient's enrollment|Progression-free survival(PFS), Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., 1 year after the last patient's enrollment|Safety as measured by the rate of AEs, The incidence and severity of adverse events (AEs) and serious adverse events (SAEs), 1 year after the last patient's enrollment
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.